Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS ...Middle East

PR Newswire - News
Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS
EMA accelerated assessment allows a shorter review period for leniolisib from a standard 210 days to 150 days Pharming is on track to submit its Marketing Authorisation Application for leniolisib in H2 2022 LEIDEN, the Netherlands, Aug. 1, 2022 /PRNewswire/ -- Pharming Group N.V....

Read More Details
Finally We wish PressBee provided you with enough information of ( Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS )

Also on site :